Oncotarget

Research Papers:

Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with 64Cu-labeled cetuximab to treat early- and late-phase peritoneal dissemination in human gastrointestinal cancer xenografts

Yukie Yoshii _, Mitsuyoshi Yoshimoto, Hiroki Matsumoto, Hideaki Tashima, Yuma Iwao, Hiroyuki Takuwa, Eiji Yoshida, Hidekatsu Wakizaka, Taiga Yamaya, Ming-Rong Zhang, Aya Sugyo, Sayaka Hanadate, Atsushi B. Tsuji and Tatsuya Higashi

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:28935-28950. https://doi.org/10.18632/oncotarget.25649

Metrics: PDF 584 views  |   HTML 1002 views  |   ?  


Abstract

Yukie Yoshii1, Mitsuyoshi Yoshimoto2, Hiroki Matsumoto3, Hideaki Tashima1, Yuma Iwao1, Hiroyuki Takuwa1, Eiji Yoshida1, Hidekatsu Wakizaka1, Taiga Yamaya1, Ming-Rong Zhang1, Aya Sugyo1, Sayaka Hanadate1, Atsushi B. Tsuji1 and Tatsuya Higashi1

1National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

2Division of Functional Imaging, National Cancer Center Hospital East, Chiba, Japan

3Research Center, Nihon Medi-Physics Co., Ltd., Chiba, Japan

Correspondence to:

Yukie Yoshii, email: yoshii.yukie@qst.go.jp

Keywords: integrated 64Cu therapy; PET-guided surgery; OpenPET; 64Cu-intraperitoneal radioimmunotherapy; 64Cu-labeled cetuximab

Received: April 04, 2018     Accepted: June 03, 2018     Published: June 22, 2018

ABSTRACT

Peritoneal dissemination is a common cause of death from gastrointestinal cancers and is difficult to treat using current therapeutic options, particularly late-phase disease. Here, we investigated the feasibility of integrated therapy using 64Cu-intraperitoneal radioimmunotherapy (ipRIT), alone or in combination with positron emission tomography (PET)-guided surgery using a theranostic agent (64Cu-labeled anti-epidermal growth factor receptor antibody cetuximab) to treat early- and late-phase peritoneal dissemination in mouse models. In this study, we utilized the OpenPET system, which has open space for conducting surgery while monitoring objects at high resolution in real time, as a novel approach to make PET-guided surgery feasible. 64Cu-ipRIT with cetuximab inhibited tumor growth and prolonged survival with little toxicity in mice with early-phase peritoneal dissemination of small lesions. For late-phase peritoneal dissemination, a combination of 64Cu-ipRIT for down-staging and subsequent OpenPET-guided surgery for resecting large tumor masses effectively prolonged survival. OpenPET clearly detected tumors (≥3 mm in size) behind other organs in the peritoneal cavity and was useful for confirming the presence or absence of residual tumors during an operation. These findings suggest that integrated 64Cu therapy can serve as a novel treatment strategy for peritoneal dissemination.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25649